PEPTIC ULCER DRUGS MARKET ANALYSIS

Regional Analysis

Global Peptic Ulcer Drugs Market- Regional Analysis

Among all regions, North America is expected to dominate the global market over the forecast period. This is attributed to North America holding a XX% market share and an increase in product approval by the regulatory bodies in this region. For instance, in June 2022, Zydus Lifesciences, a pharmaceutical company, announced that the company has received approval from the U.S Food and Drug Administration (FDA) to market Famotidine tablets in the strengths of 20 mg and 40 mg. Famotidine is a histamine H2 receptor blocker. It works by reducing the amount of acid in the stomach.

The European region is expected to be the second-dominating region over the forecast period, due to increase in the adoption of inorganic growth strategies such as acquisition by the key players in the market. For instance, in October 2021, Sandoz, a pharmaceutical company, has announced that the company has completed the acquisition of GSK’s cephalosporin antibiotics. Through this transaction, Sandoz has acquired rights to three established brands (Zinnat, Zinacef and Fortum)) in more than 100 markets, further reinforcing its leading global position in antibiotics.

Geographies Covered:

• North America: U.S. and Canada
• Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
• Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
• Middle East: GCC Countries, Israel, and Rest of Middle East
• Africa: South Africa, North Africa, and Central Africa